BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775 [PMID: 26478668 DOI: 10.3748/wjg.v21.i38.10760] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Mcconachie SM, Wilhelm SM, Kale-pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2015;9:287-302. [DOI: 10.1586/17512433.2016.1129272] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
2 Jakobsen JC, Nielsen EE, Feinberg J, Fobian K, Katakam KK, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C, Jakobsen JC. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd012143] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Song ATW, Sobesky R, Vinaixa C, Dumortier J, Radenne S, Durand F, Calmus Y, Rousseau G, Latournerie M, Feray C, Delvart V, Roche B, Haim-Boukobza S, Roque-Afonso AM, Castaing D, Abdala E, D’Albuquerque LAC, Duclos-Vallée JC, Berenguer M, Samuel D. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World J Gastroenterol 2016; 22(18): 4547-4558 [PMID: 27182164 DOI: 10.3748/wjg.v22.i18.4547] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Croome KP, Mathur AK, Pungpapong S, Lee DD, Moss AA, Rosen CB, Heimbach JK, Taner CB. Equivalent Outcomes With Retransplantation and Primary Liver Transplantation in the Direct-acting Antiviral Era. Transplantation 2019;103:1168-74. [DOI: 10.1097/tp.0000000000002460] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
6 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
7 Yong KSM, Her Z, Chen Q. Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells 2019;8:E604. [PMID: 31213010 DOI: 10.3390/cells8060604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
8 Berumen J, Hemming A. Liver Retransplantation. Clinics in Liver Disease 2017;21:435-47. [DOI: 10.1016/j.cld.2016.12.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, Rapaccini GL, Pompili M, Gasbarrini A. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol 2017; 9(7): 352-367 [PMID: 28321272 DOI: 10.4254/wjh.v9.i7.352] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
10 Alfageme Zubillaga M, Fontanilla Echeveste T, Pérez González I, Royuela Vicente A, Duca A, Ruiz Peralbo R, González Hernando C. Elastografía tipo ARFI: modificación tras tratamiento antiviral en el trasplante hepático con recidiva por VHC. Radiología 2017;59:139-46. [DOI: 10.1016/j.rx.2016.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Due OT, Chaikledkaew U, Genuino AJM, Sobhonslidsuk A, Thakkinstian A. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. Biomed Res Int 2019;2019:2301291. [PMID: 31815126 DOI: 10.1155/2019/2301291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
13 Bashir MH, Fazili J, Madhoun MF, Kanagala R, Chen S, Nusrat S. Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis. Eur J Gastroenterol Hepatol 2018;30:296-301. [PMID: 29200006 DOI: 10.1097/MEG.0000000000001032] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Sáez-González E, Vinaixa C, San Juan F, Hontangas V, Benlloch S, Aguilera V, Rubín A, García M, Prieto M, López-Andujar R, Berenguer M. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int 2018;38:1022-7. [PMID: 29105320 DOI: 10.1111/liv.13618] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
15 Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 2016;27:1467-74. [PMID: 27226385 DOI: 10.1093/annonc/mdw219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
16 Kumar S, Deo SV, Altarabsheh SE, Dunlay SM, Sarabu N, Sareyyupoglu B, Elgudin Y, Medalion B, Elamm C, Ginwalla M, Zacharias M, Benatti R, Oliveira GH, Kilic A, Fonarow GC, Park SJ. Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from the United Network for Organ Sharing Database). The American Journal of Cardiology 2016;118:132-7. [DOI: 10.1016/j.amjcard.2016.04.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
17 Cholankeril G, Yoo ER, Hu M, Gadiparthi C, Khan MA, Perumpail RB, Bonham CA, Ahmed A. Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents. J Viral Hepat 2017;24:1194-5. [DOI: 10.1111/jvh.12750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Maekawa S, Enomoto N. The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan. J Gastroenterol 2018;53:1168-9. [PMID: 29980847 DOI: 10.1007/s00535-018-1493-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS One 2018;13:e0197544. [PMID: 29874250 DOI: 10.1371/journal.pone.0197544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Moreno-Planas JM, Larrubia-Marfil JR, Sánchez-Ruano JJ, Morillas-Ariño J, Patón-Arenas R, Sáiz-Chumillas RM, Tébar-Romero E, Lucendo-Villarín A, Gancedo-Bringas P, Solera-Muñoz M, Vicente-Gutiérrez MDM, Martínez-Alfaro E. Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir. Enferm Infecc Microbiol Clin (Engl Ed) 2018;36:277-83. [PMID: 28641865 DOI: 10.1016/j.eimc.2017.05.001] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]